Flora Peyvandi/X
Oct 21, 2025, 06:43
Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X.
”Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec. Results from the BENEGENE-2 trial.”
Read more here.
Stay updated with Hemostasis Today.
-
Nov 10, 2026, 06:20Vida Shafti: Can AI Help Us Predict Thrombosis before it Happens in Assisted Reproduction?
-
Nov 10, 2026, 06:11Michaël Prüfer: Treatment of Varicose Veins with Laser Endoveineux Total
-
Nov 10, 2026, 05:55Sandhya Selvakumar: Guide to Stroke Classification and Rehabilitation
-
Nov 9, 2026, 22:47Avirup Guha: Early Immune Responses to Androgen Deprivation Therapy and Coronary Plaque Progression
-
Nov 9, 2026, 22:42Angela Forsyth: Joining Novo Nordisk as Medical Liaison for the Ohio Valley Region
-
Nov 9, 2026, 22:36Vladimir Otasevic: Presenting Thromboprophylaxis and Treatment of VTE in Patients With Malignancy
-
Nov 9, 2026, 22:28Dragoș Claudiu Popescu: Corticosteroid Exposure and Thrombotic Risk in ITP
-
Nov 9, 2026, 22:20Cedric Ghevaert: How RNA Processing Defects Affect Megakaryocytes in TAR Syndrome
-
Nov 9, 2026, 22:07Todd C. Villines: PARAMOUNT Shows Benefits of Coronary Plaque-Based Care in Stable Symptomatic Patients